Recently, a new class of therapeutics that disable the neonatal Fc receptor (FcRn), which protects IgG from degradation, has emerged to treat IgG-mediated autoimmune disease. 4,5 Here, we review ...

Previous studies established defective Fc receptor mediated clearance in patients with systemic lupus erythematosis (SLE), a disorder associated with circulating immune complexes (CIC).

The Dutch biotech company said the product was the first and only neonatal Fc receptor blocker approved to treat the condition. The product is co-formulated with Halozyme Therapeutics’ (HALO ...

Roivant Sciences secures $5.2B for advancing late-stage drugs like IMVT-1402 & brepocitinib. Click here to read an analysis ...

Viridian Therapeutics, Inc.’s VRDN share price has surged by 5.71%, which has investors questioning if this is right time to ...

The US FDA has cleared the IND application of Aclaris to commence the placebo-controlled Phase Ia/Ib study of the ATI-052 ...

Here we describe a mouse Fc receptor, designated Fcα/μR, and its human homolog, that bind both IgM and IgA with intermediate or high affinity. Fcα/μR is constitutively expressed on the ...

The company said that Vyvgart (efgartigimod alfa) is the first novel mechanism of action for CIDP treatment in more than 30 years.

Health system pharmacists and physicians are monitoring a wave of expected new drug approvals between late 2024 and third quarter of 2025. A recent article published in the American Journal of ...

This study presents a valuable finding on the direct cytotoxic effects of DuoHexaBody-CD37 in diffuse large B-cell lymphoma, mediated via SHP-1 activation and antibody clustering, independent of ...